The Experts below are selected from a list of 68997 Experts worldwide ranked by ideXlab platform

Michael Boeckh - One of the best experts on this subject based on the ideXlab platform.

  • The serum galactomannan index predicts mortality in hematopoietic stem Cell Transplant recipients with invasive aspergillosis
    Clinical Infectious Diseases, 2013
    Co-Authors: Cynthia E. Fisher, A. Michal Stevens, Steven A. Pergam, Michael Boeckh, Wendy Leisenring, Tobias M. Hohl
    Abstract:

    We examined the relationship between serum and bronchoalveolar lavage (BAL) galactomannan index (GMI) values and mortality in allogeneic hematopoietic Cell Transplant recipients with invasive pulmonary aspergillosis. Using a clinical sign and symptom-initiated approach, we found that the serum but not the BAL GMI level correlated with 42- and 180-day patient mortality.

  • guidelines for preventing infectious complications among hematopoietic Cell Transplant recipients a global perspective
    Bone Marrow Transplantation, 2009
    Co-Authors: M Tomblyn, Kent A Sepkowitz, Jo Anne H Young, Tom Chiller, Herman Einsele, Ronald E Gress, Jan Storek, John R Wingard, Michael Boeckh
    Abstract:

    Guidelines for preventing infectious complications among hematopoietic Cell Transplant recipients: a global perspective

  • randomized controlled multicenter trial of aerosolized ribavirin for respiratory syncytial virus upper respiratory tract infection in hematopoietic Cell Transplant recipients
    Clinical Infectious Diseases, 2007
    Co-Authors: Jane Kuypers, Michael Boeckh, Janet A Englund, Yufeng Li, Carole B Miller, Alan S Cross, Humberto Fernandez, Hyung W Kim
    Abstract:

    Background. Respiratory syncytial virus infection of the upper airways may progress to fatal pneumonia in hematopoietic Cell Transplant recipients. The safety and efficacy of aerosolized ribavirin in preventing disease progression is unknown. Methods. In a multicenter prospective trial, hematopoietic Cell Transplant recipients with respiratory syncytial virus infection of the upper airways were randomized to receive ribavirin (2 g 3 times daily) or supportive care for 10 days. The primary end point was progression to radiographically proven pneumonia. Secondary end points included virologically proven respiratory syncytial virus pneumonia, viral load changes, and safety. Results. Fourteen patients were randomized to 1 of 2 treatment arms. The trial was discontinued after 5 years because of slow accrual. Pneumonia at 1 month after randomization occurred in 1 of 9 patients who received ribavirin and in 2 of 5 patients who received supportive care (P = .51); virologically proven respiratory syncytial virus pneumonia occurred in 0 of 9 and 2 of 5 patients, respectively (P = .11). At 10 days after randomization, the average viral load decreased by 0.75 log 10 copies/mL in ribavirin recipients, compared with a viral load increase of 1.26 log 10 copies/mL in untreated patients (P = .07). No discontinuations of ribavirin therapy because of adverse effects occurred during 84 drug administrations. Rates of adverse events were similar in both groups. Conclusions. Preemptive aerosolized ribavirin treatment appeared to be safe, and trends of decreasing viral load over time were observed. However, proof of efficacy remains elusive in hematopoietic Cell Transplant recipients.

  • brief communication fatal human metapneumovirus infection in stem Cell Transplant recipients
    Annals of Internal Medicine, 2006
    Co-Authors: Janet A Englund, Rhoda Morrow, Garrett W Nichols, David N. Fredricks, Robert C Hackman, Jane Kuypers, Michael Boeckh, Lawrence Corey
    Abstract:

    Background: Human metapneumovirus (hMPV), a recently discovered respiratory virus, is associated with clinical disease in young and elderly persons. Objective: To determine the importance of hMPV in hematopoietic stem-Cell Transplant recipients. Design: Retrospective survey of patients with consecutive residual bronchoalveolar lavage (BAL) samples. Setting: Referral cancer center. Patients: Hematopoietic stem-Cell Transplant recipients who underwent BAL because of lower respiratory tract disease. Measurements: Bronchoalveolar lavage specimens were assayed by quantitative real-time polymerase chain reaction methods. Results: Human metapneumovirus was detected in BAL specimens from 5 of 163 patients (3.0%). Persistent viral infection was noted in 3 patients with several samples, and hMPV was detected in 1 of 2 lung specimens tested. Infected patients became symptomatic within the first 40 days after Transplantation. Initial symptoms included fever, cough, nasal congestion, and sore throat. Clinical findings included respiratory failure, pulmonary hemorrhage, and culture-negative septic shock. Four of 5 patients died with acute respiratory failure. Limitations: This retrospective study did not evaluate asymptomatic patients or those with mild disease. Conclusion: Human metapneumovirus infection in the lower respiratory tract is associated with respiratory failure in immunocompromised adults who were previously considered to have "idiopathic pneumonia." The infection may result in fulminant respiratory decompensation and shock after Transplantation.

  • Brief communication: fatal human metapneumovirus infection in stem-Cell Transplant recipients.
    Annals of Internal Medicine, 2006
    Co-Authors: Janet A Englund, David N. Fredricks, Robert C Hackman, Jane Kuypers, Michael Boeckh, W. Garrett Nichols, Rhoda Ashley Morrow, Lawrence Corey
    Abstract:

    Human metapneumovirus (hMPV) usually affects children and the elderly. The authors found hMPV in bronchoalveolar lavage specimens from 5 of 163 hematopoietic stem-Cell Transplant recipients (3.0%) ...

Janet A Englund - One of the best experts on this subject based on the ideXlab platform.

  • randomized controlled multicenter trial of aerosolized ribavirin for respiratory syncytial virus upper respiratory tract infection in hematopoietic Cell Transplant recipients
    Clinical Infectious Diseases, 2007
    Co-Authors: Jane Kuypers, Michael Boeckh, Janet A Englund, Yufeng Li, Carole B Miller, Alan S Cross, Humberto Fernandez, Hyung W Kim
    Abstract:

    Background. Respiratory syncytial virus infection of the upper airways may progress to fatal pneumonia in hematopoietic Cell Transplant recipients. The safety and efficacy of aerosolized ribavirin in preventing disease progression is unknown. Methods. In a multicenter prospective trial, hematopoietic Cell Transplant recipients with respiratory syncytial virus infection of the upper airways were randomized to receive ribavirin (2 g 3 times daily) or supportive care for 10 days. The primary end point was progression to radiographically proven pneumonia. Secondary end points included virologically proven respiratory syncytial virus pneumonia, viral load changes, and safety. Results. Fourteen patients were randomized to 1 of 2 treatment arms. The trial was discontinued after 5 years because of slow accrual. Pneumonia at 1 month after randomization occurred in 1 of 9 patients who received ribavirin and in 2 of 5 patients who received supportive care (P = .51); virologically proven respiratory syncytial virus pneumonia occurred in 0 of 9 and 2 of 5 patients, respectively (P = .11). At 10 days after randomization, the average viral load decreased by 0.75 log 10 copies/mL in ribavirin recipients, compared with a viral load increase of 1.26 log 10 copies/mL in untreated patients (P = .07). No discontinuations of ribavirin therapy because of adverse effects occurred during 84 drug administrations. Rates of adverse events were similar in both groups. Conclusions. Preemptive aerosolized ribavirin treatment appeared to be safe, and trends of decreasing viral load over time were observed. However, proof of efficacy remains elusive in hematopoietic Cell Transplant recipients.

  • brief communication fatal human metapneumovirus infection in stem Cell Transplant recipients
    Annals of Internal Medicine, 2006
    Co-Authors: Janet A Englund, Rhoda Morrow, Garrett W Nichols, David N. Fredricks, Robert C Hackman, Jane Kuypers, Michael Boeckh, Lawrence Corey
    Abstract:

    Background: Human metapneumovirus (hMPV), a recently discovered respiratory virus, is associated with clinical disease in young and elderly persons. Objective: To determine the importance of hMPV in hematopoietic stem-Cell Transplant recipients. Design: Retrospective survey of patients with consecutive residual bronchoalveolar lavage (BAL) samples. Setting: Referral cancer center. Patients: Hematopoietic stem-Cell Transplant recipients who underwent BAL because of lower respiratory tract disease. Measurements: Bronchoalveolar lavage specimens were assayed by quantitative real-time polymerase chain reaction methods. Results: Human metapneumovirus was detected in BAL specimens from 5 of 163 patients (3.0%). Persistent viral infection was noted in 3 patients with several samples, and hMPV was detected in 1 of 2 lung specimens tested. Infected patients became symptomatic within the first 40 days after Transplantation. Initial symptoms included fever, cough, nasal congestion, and sore throat. Clinical findings included respiratory failure, pulmonary hemorrhage, and culture-negative septic shock. Four of 5 patients died with acute respiratory failure. Limitations: This retrospective study did not evaluate asymptomatic patients or those with mild disease. Conclusion: Human metapneumovirus infection in the lower respiratory tract is associated with respiratory failure in immunocompromised adults who were previously considered to have "idiopathic pneumonia." The infection may result in fulminant respiratory decompensation and shock after Transplantation.

  • Brief communication: fatal human metapneumovirus infection in stem-Cell Transplant recipients.
    Annals of Internal Medicine, 2006
    Co-Authors: Janet A Englund, David N. Fredricks, Robert C Hackman, Jane Kuypers, Michael Boeckh, W. Garrett Nichols, Rhoda Ashley Morrow, Lawrence Corey
    Abstract:

    Human metapneumovirus (hMPV) usually affects children and the elderly. The authors found hMPV in bronchoalveolar lavage specimens from 5 of 163 hematopoietic stem-Cell Transplant recipients (3.0%) ...

Lawrence Corey - One of the best experts on this subject based on the ideXlab platform.

  • brief communication fatal human metapneumovirus infection in stem Cell Transplant recipients
    Annals of Internal Medicine, 2006
    Co-Authors: Janet A Englund, Rhoda Morrow, Garrett W Nichols, David N. Fredricks, Robert C Hackman, Jane Kuypers, Michael Boeckh, Lawrence Corey
    Abstract:

    Background: Human metapneumovirus (hMPV), a recently discovered respiratory virus, is associated with clinical disease in young and elderly persons. Objective: To determine the importance of hMPV in hematopoietic stem-Cell Transplant recipients. Design: Retrospective survey of patients with consecutive residual bronchoalveolar lavage (BAL) samples. Setting: Referral cancer center. Patients: Hematopoietic stem-Cell Transplant recipients who underwent BAL because of lower respiratory tract disease. Measurements: Bronchoalveolar lavage specimens were assayed by quantitative real-time polymerase chain reaction methods. Results: Human metapneumovirus was detected in BAL specimens from 5 of 163 patients (3.0%). Persistent viral infection was noted in 3 patients with several samples, and hMPV was detected in 1 of 2 lung specimens tested. Infected patients became symptomatic within the first 40 days after Transplantation. Initial symptoms included fever, cough, nasal congestion, and sore throat. Clinical findings included respiratory failure, pulmonary hemorrhage, and culture-negative septic shock. Four of 5 patients died with acute respiratory failure. Limitations: This retrospective study did not evaluate asymptomatic patients or those with mild disease. Conclusion: Human metapneumovirus infection in the lower respiratory tract is associated with respiratory failure in immunocompromised adults who were previously considered to have "idiopathic pneumonia." The infection may result in fulminant respiratory decompensation and shock after Transplantation.

  • Brief communication: fatal human metapneumovirus infection in stem-Cell Transplant recipients.
    Annals of Internal Medicine, 2006
    Co-Authors: Janet A Englund, David N. Fredricks, Robert C Hackman, Jane Kuypers, Michael Boeckh, W. Garrett Nichols, Rhoda Ashley Morrow, Lawrence Corey
    Abstract:

    Human metapneumovirus (hMPV) usually affects children and the elderly. The authors found hMPV in bronchoalveolar lavage specimens from 5 of 163 hematopoietic stem-Cell Transplant recipients (3.0%) ...

Jane Kuypers - One of the best experts on this subject based on the ideXlab platform.

  • randomized controlled multicenter trial of aerosolized ribavirin for respiratory syncytial virus upper respiratory tract infection in hematopoietic Cell Transplant recipients
    Clinical Infectious Diseases, 2007
    Co-Authors: Jane Kuypers, Michael Boeckh, Janet A Englund, Yufeng Li, Carole B Miller, Alan S Cross, Humberto Fernandez, Hyung W Kim
    Abstract:

    Background. Respiratory syncytial virus infection of the upper airways may progress to fatal pneumonia in hematopoietic Cell Transplant recipients. The safety and efficacy of aerosolized ribavirin in preventing disease progression is unknown. Methods. In a multicenter prospective trial, hematopoietic Cell Transplant recipients with respiratory syncytial virus infection of the upper airways were randomized to receive ribavirin (2 g 3 times daily) or supportive care for 10 days. The primary end point was progression to radiographically proven pneumonia. Secondary end points included virologically proven respiratory syncytial virus pneumonia, viral load changes, and safety. Results. Fourteen patients were randomized to 1 of 2 treatment arms. The trial was discontinued after 5 years because of slow accrual. Pneumonia at 1 month after randomization occurred in 1 of 9 patients who received ribavirin and in 2 of 5 patients who received supportive care (P = .51); virologically proven respiratory syncytial virus pneumonia occurred in 0 of 9 and 2 of 5 patients, respectively (P = .11). At 10 days after randomization, the average viral load decreased by 0.75 log 10 copies/mL in ribavirin recipients, compared with a viral load increase of 1.26 log 10 copies/mL in untreated patients (P = .07). No discontinuations of ribavirin therapy because of adverse effects occurred during 84 drug administrations. Rates of adverse events were similar in both groups. Conclusions. Preemptive aerosolized ribavirin treatment appeared to be safe, and trends of decreasing viral load over time were observed. However, proof of efficacy remains elusive in hematopoietic Cell Transplant recipients.

  • brief communication fatal human metapneumovirus infection in stem Cell Transplant recipients
    Annals of Internal Medicine, 2006
    Co-Authors: Janet A Englund, Rhoda Morrow, Garrett W Nichols, David N. Fredricks, Robert C Hackman, Jane Kuypers, Michael Boeckh, Lawrence Corey
    Abstract:

    Background: Human metapneumovirus (hMPV), a recently discovered respiratory virus, is associated with clinical disease in young and elderly persons. Objective: To determine the importance of hMPV in hematopoietic stem-Cell Transplant recipients. Design: Retrospective survey of patients with consecutive residual bronchoalveolar lavage (BAL) samples. Setting: Referral cancer center. Patients: Hematopoietic stem-Cell Transplant recipients who underwent BAL because of lower respiratory tract disease. Measurements: Bronchoalveolar lavage specimens were assayed by quantitative real-time polymerase chain reaction methods. Results: Human metapneumovirus was detected in BAL specimens from 5 of 163 patients (3.0%). Persistent viral infection was noted in 3 patients with several samples, and hMPV was detected in 1 of 2 lung specimens tested. Infected patients became symptomatic within the first 40 days after Transplantation. Initial symptoms included fever, cough, nasal congestion, and sore throat. Clinical findings included respiratory failure, pulmonary hemorrhage, and culture-negative septic shock. Four of 5 patients died with acute respiratory failure. Limitations: This retrospective study did not evaluate asymptomatic patients or those with mild disease. Conclusion: Human metapneumovirus infection in the lower respiratory tract is associated with respiratory failure in immunocompromised adults who were previously considered to have "idiopathic pneumonia." The infection may result in fulminant respiratory decompensation and shock after Transplantation.

  • Brief communication: fatal human metapneumovirus infection in stem-Cell Transplant recipients.
    Annals of Internal Medicine, 2006
    Co-Authors: Janet A Englund, David N. Fredricks, Robert C Hackman, Jane Kuypers, Michael Boeckh, W. Garrett Nichols, Rhoda Ashley Morrow, Lawrence Corey
    Abstract:

    Human metapneumovirus (hMPV) usually affects children and the elderly. The authors found hMPV in bronchoalveolar lavage specimens from 5 of 163 hematopoietic stem-Cell Transplant recipients (3.0%) ...

Christopher E Dandoy - One of the best experts on this subject based on the ideXlab platform.

  • outcomes following autologous hematopoietic stem Cell Transplant for patients with relapsed wilms tumor a cibmtr retrospective analysis
    Bone Marrow Transplantation, 2017
    Co-Authors: Marcio H Malogolowkin, Michael T Hemmer, Jennifer Lerademacher, Gregory A Hale, Parinda A Mehta, Angela R Smith, Carrie L Kitko, Allistair Abraham, Hisham Abdelazim, Christopher E Dandoy
    Abstract:

    Despite the marked improvement in the overall survival (OS) for patients diagnosed with Wilms' tumor (WT), the outcomes for those who experience relapse have remained disappointing. We describe the outcomes of 253 patients with relapsed WT who received high-dose chemotherapy (HDT) followed by autologous hematopoietic stem Cell Transplant (HCT) between 1990 and 2013, and were reported to the Center for International Blood and Marrow Transplantation Research. The 5-year estimates for event-free survival (EFS) and OS were 36% (95% confidence interval (CI); 29-43%) and 45% (95 CI; 38-51%), respectively. Relapse of primary disease was the cause of death in 81% of the population. EFS, OS, relapse and Transplant-related mortality showed no significant differences when broken down by disease status at Transplant, time from diagnosis to Transplant, year of Transplant or conditioning regimen. Our data suggest that HDT followed by autologous HCT for relapsed WT is well tolerated and outcomes are similar to those reported in the literature. As attempts to conduct a randomized trial comparing maintenance chemotherapy with consolidation versus HDT followed by stem Cell Transplant have failed, one should balance the potential benefits with the yet unknown long-term risks. As disease recurrence continues to be the most common cause of death, future research should focus on the development of consolidation therapies for those patients achieving complete response to therapy.

  • a complete histologic approach to gastrointestinal biopsy from hematopoietic stem Cell Transplant patients with evidence of Transplant associated gastrointestinal thrombotic microangiopathy
    Archives of Pathology & Laboratory Medicine, 2017
    Co-Authors: Mikako Warren, Sonata Jodele, Christopher E Dandoy, Kasiani C Myers, Gregory Wallace, Adam S Nelson, Javier Elbietar
    Abstract:

    Context.— Transplant-associated thrombotic microangiopathy is a serious complication of hematopoietic stem Cell Transplant that may progress to multi-organ dysfunction. Transplant-associated thrombotic microangiopathy may involve the intestinal vasculature (intestinal Transplant-associated thrombotic microangiopathy [iTMA]), causing patients to experience debilitating symptoms of ischemic colitis, including disproportionately severe abdominal pain and gastrointestinal bleeding, requiring heavy narcotic use and frequent transfusion support. Pathophysiology remains poorly investigated but may include endothelial damage mediated by inflammatory markers and the complement system. Endoscopy of hematopoietic stem Cell Transplant patients often produces biopsy samples, in which mucosal lamina propria capillaries are sufficient for an evaluation of iTMA features. Objective.— To provide a detailed review of histologic features of iTMA. Data Sources.— We conducted a systematic review of studies assessing histologic...

  • ruxolitinib as salvage therapy in steroid refractory acute graft versus host disease in pediatric hematopoietic stem Cell Transplant patients
    Biology of Blood and Marrow Transplantation, 2017
    Co-Authors: Christopher E Dandoy, Adam S Nelson, Pooja Khandelwal, Ashley Teusinkcross, Stella M Davies, Javier Elbietar
    Abstract:

    Abstract We describe our retrospective clinical experience with ruxolitinib for steroid-refractory acute graft-versus-host disease (GVHD) in pediatric allogeneic hematopoietic stem Cell Transplant (HSCT) patients. Ruxolitinib was administered orally at 5 mg twice daily for children ≥ 25 kg or 2.5 mg twice daily if